Search

Holger Karsunky

from Redwood City, CA
Age ~32
Get Report
Connected to:
David B Kart, 67Jonathan J Kart, 63Thomas Kart, 78Alican Kartal, 49Figen Kartal, 47Necla Kartal, 59Serdar Kartal, 67Glen A Kartalis, 29Christen D Kartaltepe, 44Christian M Kartanowicz, 55

Holger Karsunky Phones & Addresses

  • 1615 Lark Ave, Redwood City, CA 94061
  • 2764 Delaware Ave, Redwood City, CA 94061
  • San Mateo, CA
  • Mountain View, CA
  • South San Francisco, CA

Work

Company: Cellerant therapeutics Aug 2005 Address: San Carlos, CA Position: Director, preclincial development

Education

Degree: PhD School / High School: Universität Duisburg-Essen, Standort Essen 1995 to 2000 Specialities: Immunology

Skills

Cell Culture • Cell Biology • Facs • Stem Cells • Molecular Biology • Cell • Flow Cytometry • Pcr • Immunology • Biochemistry • Lifesciences • Cancer • Protein Chemistry • In Vivo • In Vitro

Industries

Biotechnology

Resumes

Resumes

Holger Karsunky Photo 1

Co-Founder In Residence

View page
Location:
450 east Jamie Ct, South San Francisco, CA 94080
Industry:
Biotechnology
Work:
Cellerant Therapeutics - San Carlos, CA since Aug 2005
Director, Preclincial Development
Stanford University School of Medicine Feb 2001 - Aug 2005
Post-Doctoral Fellow
Education:
Universität Duisburg-Essen, Standort Essen 1995 - 2000
PhD, Immunology Philipps-Universität Marburg 1991 - 1995
Diploma, Molecular Biology
Skills:
Cell Culture
Cell Biology
Facs
Stem Cells
Molecular Biology
Cell
Flow Cytometry
Pcr
Immunology
Biochemistry
Lifesciences
Cancer
Protein Chemistry
In Vivo
In Vitro

Publications

Us Patents

Methods And Compositions For Enhancing Engraftment Of Hematopoietic Stem Cells

View page
US Patent:
20070237752, Oct 11, 2007
Filed:
Feb 14, 2007
Appl. No.:
11/675069
Inventors:
Julie CHRISTENSEN - Boulder Creek CA, US
Holger KARSUNKY - Redwood City CA, US
International Classification:
A61K 39/00
US Classification:
424093700
Abstract:
The present disclosure relates to the field of hematopoietic stem cell transplantation. More specifically, methods, compositions and kits for improving engraftment of stem cell transplants by administering myeloid progenitor cells are provided.

Immunoglobulin And/Or Toll-Like Receptor Proteins Associated With Myelogenous Haematological Proliferative Disorders And Uses Thereof

View page
US Patent:
20110044894, Feb 24, 2011
Filed:
Mar 26, 2009
Appl. No.:
12/810006
Inventors:
Holger Karsunky - Redwood City CA, US
Assignee:
Cellerant Therapeutics, Inc. - San Carlos CA
International Classification:
A61K 51/00
C07K 16/28
C07K 16/18
A61K 39/395
C12N 5/09
C40B 30/00
C12Q 1/68
A61P 35/00
A61P 35/02
US Classification:
424 111, 5303896, 5303891, 5303873, 4241331, 4241731, 435375, 506 7, 435 6
Abstract:
The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for members of the immunoglobulin (Ig) and/or toll-like receptor superfamilies that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.

Compositions And Methods For Treating Haematological Proliferative Disorders Of Meyloid Origin

View page
US Patent:
20110059852, Mar 10, 2011
Filed:
Mar 26, 2009
Appl. No.:
12/934120
Inventors:
Holger Karsunky - Redwood City CA, US
Assignee:
Cellerant Therapeutics, Inc. - San Carlos CA
International Classification:
C40B 30/00
G01N 33/566
C12Q 1/68
G01N 33/50
US Classification:
506 7, 436501, 435 71, 435 6, 436 94
Abstract:
The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.

Antibodies That Specifically Bind To Tim3

View page
US Patent:
20130022623, Jan 24, 2013
Filed:
Jun 29, 2012
Appl. No.:
13/538778
Inventors:
Holger Karsunky - Redwood City CA, US
Ying-Ping Jiang - Lafayette CA, US
Assignee:
Cellerant Therapeutics, Inc. - San Carlos CA
International Classification:
C07K 16/28
C07K 16/30
C12N 5/09
G01N 21/64
G01N 33/574
A61P 35/00
A61P 35/02
A61K 39/395
C12N 5/0783
US Classification:
4241731, 5303917, 4241781, 5303896, 5303873, 435375, 435 723
Abstract:
Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.

Compositions And Methods For Treating Haematological Proliferative Disorders Of Myeloid Origin

View page
US Patent:
20130216558, Aug 22, 2013
Filed:
Feb 11, 2013
Appl. No.:
13/764492
Inventors:
Holger KARSUNKY - Redwood City CA, US
Assignee:
Cellerant Therapeutics, Inc. - San Carlos CA
International Classification:
A61K 39/395
A61K 45/06
US Classification:
4241741, 435375, 4241781
Abstract:
The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.

Antibodies Specific For Cll-1

View page
US Patent:
20130295118, Nov 7, 2013
Filed:
Mar 11, 2013
Appl. No.:
13/794525
Inventors:
Holger Karsunky - Redwood City CA, US
Rob Tressler - Soquel CA, US
Assignee:
Cellerant Therapeutics, Inc. - San Carlos CA
International Classification:
C07K 16/30
A61K 47/48
US Classification:
4241741, 5303897, 5303873, 5303917, 5303913, 4241781, 435 723
Abstract:
Provided herein are antibodies specific for CLL-1.

Antibodies Specific For Cll-1

View page
US Patent:
20180273633, Sep 27, 2018
Filed:
Dec 22, 2017
Appl. No.:
15/853056
Inventors:
- San Carlos CA, US
Holger Karsunky - Redwood City CA, US
Rob Tressler - Soquel CA, US
International Classification:
C07K 16/30
A61K 47/68
C07K 16/28
Abstract:
Provided herein are antibodies specific for CLL-1.

Anti-Dll3 Antibody Drug Conjugates And Methods Of Use

View page
US Patent:
20180243435, Aug 30, 2018
Filed:
Aug 19, 2016
Appl. No.:
15/753509
Inventors:
- NORTH CHICAGO IL, US
BRIAN SLINGERLAND - SOUTH SAN FRANCISCO CA, US
TAE HAN - WOODINVILLE WA, US
JOHN PEATTIE - SAN FRANCISCO CA, US
HOLGER KARSUNKY - REDWOOD CITY CA, US
WADE C. ANDERSON - FAIRFIELD CA, US
Assignee:
ABBVIE STEMCENTRX LLC - NORTH CHICAGO IL
International Classification:
A61K 47/68
C07K 16/18
A61P 35/00
Abstract:
Provided are novel anti-DLL3 antibodies and antibody drug conjugates, and methods of using such anti-DLL3 antibodies and antibody drug conjugates to treat cancer.
Control profile
Holger Karsunky from Redwood City, CA, age ~32 Get Report